A Phase 3 interventional study of Pregabalin (Lyrica) in Neuralgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 6 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-22.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.
Among the 50 studies testing pregabalin in Neuralgia, this one is the 23rd largest by enrollment, is the only one that started in 2004, is one of 18 in phase 3, and was the 11th registered.
1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.
Browse Neuralgia studies →4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Recruiting first, the newest first:
Moumtzidou Maria Aikaterini · Sites in Greece
Ages 18+ · Women only
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 18–75
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–75
Helsinki University Central Hospital · Sites in Finland
Ages 18–75
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 154 Neuralgia studies recruiting now, 78 (51%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 19 · Phase 4 12
First in 2002; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is above the median of 52 across 833 interventional studies indexed under Neuralgia.
Median enrollment 109 across the 50 interventional studies. Of the 35 that completed or were terminated, 10 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
25 studies in Neuralgia by Viatris Inc.: none open now, none under way, none of them phase 3. Of 23 finished, 17 (74%) have results posted.
Among the 25 studies in Neuralgia by Viatris Inc., this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2004, is one of 8 in phase 3, and was the 9th registered.
Viatris Inc.’s Neuralgia studies by the year they started, since 2004.
2 of the studies testing pregabalin in Neuralgia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07712913Phase 3Brainfarma Industria Química e Farmacêutica S/AExtended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia | 2027-06-01 |
| NCT07880223Moumtzidou Maria AikateriniComparison of Two Postoperative Care Strategies After Breast Surgery | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 50 studies testing pregabalin in Neuralgia, from their registry updates:
Among Viatris Inc.’s 25 in Neuralgia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of Lyrica in Indian patients with nerve pain
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
(none)
Drug: Pregabalin (Lyrica)
Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.
Change from baseline in Short Form McGill Pain Questionnaire (SF-MPQ) visual analog score (VAS)
Time frame: Weeks 1 and 2 and end of treatment
Change from baseline in weekly mean pain scores
Time frame: Weeks 1 and 2 and end of treatment
Change from baseline in Euro Quality of Life Questionnaire (EQ-5D) scores
Time frame: End of treatment
Adverse events and laboratory value changes
Time frame: Weeks 1 and 2 and end of treatment
Change from baseline in weekly mean sleep interference score
Time frame: Weeks 1 and 2 and end of treatment
Change from baseline in sensory, affective, and total components of the pain descriptor score and the Present Pain Intensity (PPI) of the SF-MPQ
Time frame: Weeks 1 and 2 and end of treatment
Change from baseline in Patient Global Impression of Change (PGIC)
Time frame: Weeks 1 and 2 and end of treatment
Change from baseline in Clinical Global Impression of Change (CGIC)
Time frame: Weeks 1 and 2 and end of treatment
Change from baseline in pain interference scores on the Brief Pain Inventory (BPI ) Short-Form
Time frame: End of treatment
The record gives a start of Nov 2004 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →